Related Experiment Videos
Vaccination of patients with solid tumours
G Parmiani1, L Pilla, C Castelli
1Unit of Immunotherapy of Human Tumours, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy. giorgio.parmiani@istitutotumori.mi.it
Summary
Molecularly characterized tumor antigens are being used in vaccines to treat cancer. While some patients experience durable regressions, new methods like dendritic cell therapy show promise for improving outcomes.
Area of Science:
- Immunology
- Oncology
- Vaccine Development
Background:
- Molecular characterization of human tumor antigens recognized by T cells has spurred interest in cancer immunotherapy.
- Previous vaccine strategies using well-defined antigens have shown limited clinical efficacy.
Purpose of the Study:
- To evaluate the immunogenicity and clinical efficacy of vaccines targeting molecularly characterized tumor antigens.
- To discuss the limitations of current antigen-based cancer vaccine approaches.
- To explore potential strategies for improving therapeutic outcomes.
Main Methods:
- In vitro immunogenicity assessment of novel tumor antigens.
- Clinical trials involving peptide- or DNA-based vaccines encoding tumor antigens.
- Ex vivo loading of dendritic cells with tumor antigens for therapeutic administration.
Main Results:
- Vaccine administration resulted in complete and durable tumor regressions in 5-25% of patients.
- Limited clinical efficacy observed with peptide- and DNA-based antigen vaccines.
- Dendritic cell-based therapy shows potential for achieving high frequencies of tumor-specific immune responses.
Conclusions:
- Antigen-specific cancer vaccines have shown some success but face limitations in efficacy.
- Dendritic cell-based immunotherapy represents a promising approach to enhance anti-tumor immune responses.
- Further research is needed to overcome clinical limitations and improve cancer vaccine outcomes.